Risk of Stroke and Myocardial Infarction Among Initiators of Triptans
JAMA Neurol 81:248-254, Petersen,C.L.,et al, 2024
Non-ST-Elevation Myocardial Infarction in Patients Undergoing Carotid Endarterectomy or Carotid Artery Stent Placement
Stroke 45:595-597, Khan, A.,et al, 2014
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated with Rosiglitazone or Pioglitazone
JAMA 304:411-418,469, Graham,D.J., et al, 2010
Thrombolysis-Related Intracranial Hemorrhage, Analysis of 224 Cases from GUSTO-1 Trial with Clin Correl
Stroke 29:563-569, Gebel,J.M.,et al, 1998
Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction
Ann Int Med 129:597-604, Gurwitz,J.H.,et al, 1998
Embolic Stroke Following Thrombolytic Therapy for Myocardial Infarction in a Patient with Preexisting Ventricular Thrombi
Stroke 26:324-325, Bautista,R.E.D., 1995
Clin Features & Pathog of Intracerebral Hemorrhage after rt-PA & Heparin Therapy for Acute Myocardial Infarct
Neurol 45:649-658, Sloan,M.A.,et al, 1995
Hirudin in Acute Myocardial Infarction
Circulation 90:1624-1630, 1631, 2147994., Antman,E.M., 1994
Intracerebral Hemorrhage After Fibrinolytic Therapy for Acute Myocardial Infarction
C. R. , Stroke 24:554-557, 5233., Wijdicks,E.F.M.&Jack,Jr, 1993
Individual Risk Assessment for Intracranial Haemorrhage During Thrombolytic Therapy
Lancet 342:1523-1528, Simoons,M.L.,et al, 1993
Complications of Acute Stroke
Lancet 339:721-724, Oppenheimer,S.&Hachinski,V., 1992
The Risk of Stroke in Patients with Acute Myocardial Infarction after Thrombolytic and Antithrombotic Treatment
NEJM 327:1-6, Maggioni,A.P.,et al, 1992
Intracranial Hemorrhage After Coronoary Thrombolysis with Tissue Plsminogen Activator
Am J Med 92:384-390, Kase,C.S.,et al, 1992
Cerebrovascular Events After Myocardial Infarction:Analysis of the GISSI Trial
BMJ 302:1428-1431, Maggioni,A.P.,et al, 1991
CT patterns of Intracranial Hemorrhage Complicating Thrombolytic Therapy for Acute Myocardial Infarction
Radiology 181:555-559, Uglietta,J.P.,et al, 1991
Multiple Microembolic after Disintegration of Clot During Thrombolysis for Acute Myocardial Infarction
BMJ 299:1310-1312, Stafford,P.J.,et al, 1989
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Radiation-Induced Bilateral Oculomotor Nerve Palsy 20 Years After Radiation Treatment
Neurol 96:955-957, Grassmeyer, J.J.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Natalizumab-Related PML 2 Weeks after Negative Anti-JCV Antibody Assay
Neurol 86:484-486, Gagne, M.S.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Eur J Cancer 54:139-148, Michot, JM,.,et al, 2016
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Long-Term Cognitive Function, Neuroimaging and Quality of Life in Primary CNS Lymphoma
Neurol 81:84-92, Doolittle, N.,et al, 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Fatal PML Associated with Efalizumab Therapy
Neurol 78:458-467, Schwab,N.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Ischemic Stroke and Transient Ischemic Attack After Head and Neck Radiotherapy
Stroke 42:2410-2418, Plummer, C.,et al, 2011
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Arch Neurol 68:1156-1164, Clifford, D.B.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009